50
Participants
Start Date
October 1, 2023
Primary Completion Date
May 31, 2026
Study Completion Date
September 30, 2026
CLR 131
CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
Memorial Sloan Kettering Cancer Center, New York
Children's Hospital of Philadelphia, Philadelphia
Cincinnati Children's Hospital Medical Center, Cincinnati
University of Wisconsin, Carbone Cancer Center, Madison
UT Southwestern Medical Center, Dallas
Texas Children's Cancer Center, Baylor College of Medicine, Houston
Stanford University, Palo Alto
Hospital for Sick Children, Toronto
Lead Sponsor
National Cancer Institute (NCI)
NIH
Cellectar Biosciences, Inc.
INDUSTRY